Endocannabinoid system inXenopus laevisdevelopment: CB1 receptor dynamics
نویسندگان
چکیده
منابع مشابه
Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome
OBJECTIVE Extreme obesity is a core phenotypic feature of Prader-Willi syndrome (PWS). Among numerous metabolic regulators, the endocannabinoid (eCB) system is critically involved in controlling feeding, body weight, and energy metabolism, and a globally acting cannabinoid-1 receptor (CB1R) blockade reverses obesity both in animals and humans. The first-in-class CB1R antagonist rimonabant prove...
متن کاملDownregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.
Endocannabinoid signaling is a key regulator of synaptic neurotransmission throughout the brain. Compelling evidence shows that its perturbation leads to development of epileptic seizures, thus indicating that endocannabinoids play an intrinsic protective role in suppressing pathologic neuronal excitability. To elucidate whether long-term reorganization of endocannabinoid signaling occurs in ep...
متن کاملAutocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling.
It has been proposed that OX(1) orexin receptors and CB(1) cannabinoid receptors can form heteromeric complexes, which affect the trafficking of OX(1) receptors and potentiate OX(1) receptor signaling to extracellular signal-regulated kinase (ERK). We have recently shown that OX(1) receptor activity releases high levels of the endocannabinoid 2-arachidonoyl glycerol (2-AG), suggesting an altern...
متن کاملLipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.
A major advance in the field of cannabinoid research was the discovery of the endocannabinoid system, which is currently thought to consist of two G proteincoupled receptors (cannabinoid CB1 and CB2 receptors) and endogenous compounds such as arachidonoylethanolamide (i.e., anandamide; AEA; Fig. 1) and 2-arachidonoyl glycerol (2-AG) that can activate these receptors and are known as endocannabi...
متن کاملCharacterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
The first endocannabinoid, anandamide, was discovered in 1992. Since then, two other endocannabinoid agonists have been identified, 2-arachidonyl glycerol and, more recently, noladin ether. Here, we report the identification and pharmacological characterization of a novel endocannabinoid, virodhamine, with antagonist properties at the CB1 cannabinoid receptor. Virodhamine is arachidonic acid an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: FEBS Letters
سال: 2006
ISSN: 0014-5793
DOI: 10.1016/j.febslet.2006.02.057